Print
Email
Print Edition StoriesThursday, March 4, 2010
Isis Biopolymer brings in $3M in funding
By Mass High Tech staff
MHT's Julie Donnelly: Pharmaceuticals find drug development partners in colleges
Robotic surgery gains traction
Funding drugs for rare diseases
Rhode Island medical device company Isis Biopolymer Inc. has taken in $3 million in new funding, according to federal documents. Isis is focused on developing a drug-delivery patch called the IsisIQ.
The filing with the U.S. Securities and Exchange Commission doesn’t list the 26 investors in the equity financing round, but it does note as directors of the Providence company Marcia Hooper of Castile Ventures in Waltham, David Poor of GP Capital Partners LLC in New York and Arthur Gosnell of Stonehurst Capital Inc., also in New York.
Isis, which moved from Warwick to Providence in November of 2009, was founded in 2007 by Emma A. Durand, who serves as the company’s CEO and chief technology officer. The IsisIQ is a small, wireless patch that contains microprocessors, thin film batteries, biopolymers and proprietary adhesives. The patch can be loaded and pre-programmed to deliver a variety of drugs at specific intervals, officials said.
The startup has raised approximately $4.5 million in funding to date, according to its filings with the SEC.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
